Skip to main content
Skip to main content
INBP logo

Integrated BioPharma, Inc. (INBP) Stock Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.165 -$0.015 (-8.33%) |CouncilBullish Lean · 67 · B+
MCap: $5.12M| Vol: 15.1K| 52-wk range: $0.14 – $0.42

Market cap $5.12M is the value of all shares combined. Beta 0.36: the stock has moved about 64% less than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Integrated BioPharma, Inc. (INBP) trades at $0.165. Integrated BioPharma, Inc. (INBP) specializes in the creation, distribution, promotion, and sale of vitamins, nutritional supplements, and herbal items across the U.S., Luxembourg, and Canada. Market cap: $5.12M, Sector: Consumer defensive.

Price as of Sep 11, 2026 · Last analyzed: Jun 15, 2026
Integrated BioPharma, Inc. (INBP) specializes in the creation, distribution, promotion, and sale of vitamins, nutritional supplements, and herbal items across the U.S., Luxembourg, and Canada. The company operates through contract manufacturing for clients and by distributing proprietary and private-label wellness products via retail and online channels.

Analyst Coverage for INBP: INBP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates INBP against Consumer Defensive peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.

Watch the INBP film Every key number, told as a short cinematic story — just press play. ~2 min

No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.

Council Score · Weighted Average of 3 Disciplines
Bullish Lean 67/100 · B+

INBP: 2/2 scored disciplines lean bullish. Dominant signal: Seth Klarman bullish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated)Ray Dalio
Favorable read
Griffin-style lens (simulated)Ken Griffin
Neutral read
Simons-style lens (simulated)Jim Simons
Neutral read
Englander-style lens (simulated)Izzy Englander
Favorable read
Klarman-style lens (simulated)Seth Klarman
Favorable read
Moon AI lens (model)
Favorable read
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Neutral
Margin of Safety
Undervalued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →
The lenses are modelled on the published principles of the investors named. We are not affiliated with them, they have not endorsed this, and it is not their opinion of this stock.

Integrated BioPharma, Inc. (INBP) Consumer Business Overview

CEORiva Kay Sheppard
Employees153
HeadquartersHillside, United States
IPO Year1996

Integrated BioPharma, Inc. (INBP) operates in the consumer defensive sector, specializing in the creation, distribution, promotion, and sale of vitamins, nutritional supplements, and herbal items across the U.S., Luxembourg, and Canada. The company employs a dual strategy, encompassing contract manufacturing for diverse clients and distributing proprietary and private-label wellness products through various retail channels and online.

Data Provenance | Financial Data Quantitative Analysis Analysis: Jun 15, 2026

What Is the Investment Thesis for INBP?

AI-written as of Jun 15, 2026 — figures and tone reflect the data available then, not today's score.

Integrated BioPharma, Inc. (INBP) presents a unique operational profile within the consumer defensive sector, characterized by its dual business model encompassing both contract manufacturing and the distribution of proprietary and private-label nutraceutical products. A key value driver is the company's established presence in the growing wellness market across the U.S., Luxembourg, and Canada, leveraging its 1980 founding date for industry experience. The Contract Manufacturing segment provides a foundational revenue stream by serving diverse clients, while the Other Nutraceutical Businesses segment offers growth potential through proprietary brands like Peaceful Sleep and Wheatgrass, alongside expanding private-label and e-commerce initiatives. However, the company's financial metrics indicate areas for close investor scrutiny, including a negative profit margin of -3.4% and a low gross margin of 4.6%. With a market capitalization of $5.12M, INBP operates as a micro-cap entity. Growth catalysts include the increasing global demand for health supplements, potential expansion of its client base in contract manufacturing, and enhanced market penetration for its owned brands. The company's beta of 0.36 suggests lower volatility relative to the broader market. Risks are primarily associated with its profitability challenges, intense competition in the nutraceutical space, and the inherent characteristics of its OTC Other listing, which implies less stringent disclosure and potentially lower liquidity.

Based on FMP financials and quantitative analysis

INBP Key Highlights

AI-written as of Jun 15, 2026 — figures and tone reflect the data available then, not today's score.

Market capitalization of $5.12M, positioning INBP as a micro-cap company within the consumer defensive sector.

  • A negative profit margin of -3.4% indicates current unprofitability, requiring careful financial monitoring.
  • Gross margin stands at 4.6%, reflecting a relatively low profitability on sales before operating expenses.
  • A Beta of 0.36 suggests lower stock price volatility compared to the overall market, potentially appealing to risk-averse investors.
  • Operates with 147 employees, supporting its dual segments of contract manufacturing and nutraceutical product distribution.

Who Are INBP's Competitors?

INBP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
INDFY Indofood Agri Resources Ltd. $13.60 0.00% $380M
DDC DDC Enterprise Limited $0.25 +1.78% $6.09M
HCWC Healthy Choice Wellness Corp. $9.65 +13.53% $6.27M
PLAG Planet Green Holdings Corp. $0.72 +1.57% $10.2M
NAII Natural Alternatives International, Inc. $2.02 +1.00% $12.7M 365-pillar
COOT Australian Oilseeds Holdings Limited Ordinary Shares $0.48 +2.65% $14.3M
MWYN Marwynn Holdings, Inc. $0.93 +5.83% $18.8M
JVA Coffee Holding Co., Inc. $3.93 +14.58% $22.4M 775-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are INBP's Key Strengths?

Dual business model provides diversified revenue streams from contract manufacturing and branded product sales.

  • Established proprietary brands such as Peaceful Sleep and Wheatgrass with market presence.
  • Integrated services including manufacturing, warehousing, and order fulfillment.
  • Long operating history since 1980, indicating experience and stability in the industry.
  • Geographic presence in the U.S., Luxembourg, and Canada.

What Are INBP's Weaknesses?

Negative profit margin of -3.4% indicates current unprofitability.

  • Low gross margin of 4.6% suggests limited pricing power or high production costs.
  • Small market capitalization of $5.12M, potentially limiting access to capital.
  • OTC Other listing implies less stringent disclosure requirements and potentially lower liquidity.
  • Unknown disclosure status, making comprehensive investor analysis challenging.

What Could Drive INBP Stock Higher?

INBP catalyst: Growing consumer demand for health and wellness products, including vitamins, nutritional supplements, and herbal items, particularly in its operating markets of the U.S., Luxembourg, and Canada.

  • Expansion of the private-label market, which could drive increased demand for INBP's private-label vitamin and supplement products offered directly online and through retail channels.
  • Potential for new product development or line extensions under its proprietary brands, such as Peaceful Sleep and Wheatgrass, to capture evolving consumer preferences and market trends.
  • Strategic partnerships or increased client acquisition within its Contract Manufacturing division, leveraging its formulation and production capabilities for dietary supplements.
  • Continued growth in e-commerce for health products, enhancing the reach and sales potential of INBP's online offerings.

What Are the Key Risks for INBP?

Financial-distress signal — its Altman Z-Score of 0.93 sits in the distress zone (elevated bankruptcy risk).

  • Negative return on equity (-8.3%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
  • Sustained negative profit margin of -3.4% and a low gross margin of 4.6% indicate persistent profitability challenges.
  • Intense competition within the fragmented nutraceutical and dietary supplement market from numerous established and emerging brands.
  • Regulatory changes or increased scrutiny in the dietary supplement industry across the U.S., Luxembourg, and Canada, which could impact product formulation, marketing, or distribution.
  • Inherent risks associated with its OTC Other listing, including potentially lower liquidity, wider bid-ask spreads, and limited public disclosure, making investment more speculative.
  • Fluctuations in raw material costs or disruptions in the supply chain for natural botanicals and other ingredients, impacting production costs and product availability.

What Are the Growth Opportunities for INBP?

  • **Expansion in Contract Manufacturing Services:** The global market for contract manufacturing in the nutraceutical sector is experiencing steady growth, driven by increasing demand for dietary supplements and functional foods, coupled with a trend among brand owners to outsource production to specialized facilities. INBP's Contract Manufacturing division, which formulates vitamins and dietary supplements for distributors, multi-level marketing firms, and healthcare practitioners, is well-positioned to capitalize on this trend. By expanding its client base, enhancing its manufacturing capabilities, and potentially diversifying its product formulation expertise, INBP could secure larger contracts and increase its market share. This growth driver offers a stable, B2B revenue stream with potential for long-term partnerships, leveraging its established operational history since 1980.
  • **Leveraging Proprietary Brands and E-commerce:** INBP's proprietary brands, including "Peaceful Sleep" and "Wheatgrass," represent a significant growth opportunity. As consumer interest in specific health solutions like sleep aids and natural wellness products continues to rise, investing in brand building, targeted marketing, and product innovation for these labels can drive increased sales and market penetration. Furthermore, the company's existing direct-to-consumer online sales channel for private-label vitamin and supplement products can be expanded. The e-commerce market for health and wellness products is projected for substantial growth, offering a cost-effective way to reach a broader customer base and build brand loyalty without extensive physical retail infrastructure.
  • **Increased Demand for Private-Label Nutraceuticals:** The market for private-label products across various retail channels, including supermarkets and specialty stores, continues to expand as retailers seek to offer more affordable alternatives and build their own brand equity. INBP's capability to offer private-label vitamin and supplement products directly online, alongside its distribution to a wide range of retail outlets, positions it to capture this growing demand. By enhancing its private-label offerings, improving supply chain efficiencies, and forging stronger partnerships with retailers, INBP can tap into this significant market segment, which often provides higher margins and greater control over product development and pricing.
  • **Geographic Market Penetration:** While INBP currently operates in the United States, Luxembourg, and Canada, there is potential for deeper penetration within these existing markets and strategic expansion into new international territories. The global nutraceutical market is diverse, with varying consumer preferences and regulatory environments. By conducting targeted market research, adapting product formulations to local tastes and regulations, and establishing new distribution partnerships, INBP could unlock new revenue streams. Focusing on regions with high growth rates for health supplements or underserved markets could provide substantial long-term growth, leveraging its existing international experience in Luxembourg and Canada.
  • **Diversification and Supply Chain Integration:** INBP's role in supplying high-quality natural botanicals, encompassing multi-minerals and various raw materials, represents an opportunity for further diversification and enhanced supply chain integration. By expanding its portfolio of raw materials and potentially offering these to a broader external client base beyond its internal needs, INBP could establish itself as a key supplier in the nutraceutical ingredient market. This vertical integration not only provides an additional revenue stream but also strengthens the company's control over the quality and cost of its own product inputs, offering a competitive advantage in terms of product integrity and manufacturing efficiency.

What Are INBP's Competitive Advantages?

  • Established dual business model combining B2B contract manufacturing with B2C branded product distribution.
  • Proprietary brands like Peaceful Sleep and Wheatgrass, which have market presence and consumer recognition.
  • Integrated supply chain capabilities, from raw material sourcing to manufacturing, warehousing, and fulfillment.
  • Long operational history since 1980, indicating deep industry experience and established relationships.
  • Geographic reach across the U.S., Luxembourg, and Canada, diversifying market exposure.

What Does INBP Do?

Integrated BioPharma, Inc. (INBP), established in 1980 and formerly known as Integrated Health Technologies, Inc., has evolved into a key player in the nutritional supplement and herbal products market. Headquartered in Hillside, New Jersey, the company's core business revolves around the creation, distribution, promotion, and sale of a diverse range of vitamins, nutritional supplements, and herbal items. Its operational footprint extends across significant markets, including the United States, Luxembourg, and Canada, reflecting a strategic international presence within the consumer defensive sector. INBP's business model is distinctly segmented into two primary divisions: Contract Manufacturing and Other Nutraceutical Businesses. The Contract Manufacturing division serves as a vital partner for a varied client base, undertaking the formulation and production of vitamins and dietary supplements. This segment caters to distributors, multi-level marketing firms, and professional healthcare practitioners, providing tailored manufacturing solutions that leverage the company's expertise in nutraceutical development. This B2B approach offers a steady revenue stream and leverages specialized production capabilities. The Other Nutraceutical Businesses segment focuses on the direct distribution of wellness-oriented nutritional products to a broad spectrum of retail outlets. These include general retailers, major supermarkets, pharmacies, and specialty vitamin stores, ensuring wide market accessibility for its offerings. This segment is notable for featuring INBP's proprietary brands, such as "Peaceful Sleep" and "Wheatgrass," alongside other owned nutraceutical labels, which are strategically positioned to capture specific consumer health trends. Furthermore, this division extends its reach through the direct online sale of private-label vitamin and supplement products, tapping into the growing e-commerce market for health goods. Complementing its product distribution, INBP also provides essential warehousing and order fulfillment services, enhancing its logistical capabilities. The company further strengthens its supply chain by supplying high-quality natural botanicals, including multi-minerals and various raw materials, to both internal operations and potentially external clients, underscoring its integrated approach to the nutraceutical value chain.

What Products and Services Does INBP Offer?

  • Formulate vitamins and dietary supplements for various clients.
  • Manufacture nutraceutical products under contract for distributors and healthcare practitioners.
  • Distribute wellness-focused nutritional products to a wide range of retail outlets.
  • Market and sell proprietary brands such as Peaceful Sleep and Wheatgrass.
  • Offer private-label vitamin and supplement products directly through online channels.
  • Provide warehousing and order fulfillment services for its products and potentially for clients.
  • Supply high-quality natural botanicals, including multi-minerals and other raw materials.
  • Operate in the United States, Luxembourg, and Canada.

How Does INBP Make Money?

  • Generates revenue from contract manufacturing services for vitamins and dietary supplements.
  • Earns income from the sale of its proprietary branded nutraceutical products to retailers and consumers.
  • Derives revenue from the sale of private-label vitamin and supplement products, primarily online.
  • Receives fees for warehousing and order fulfillment services provided.
  • Generates sales from supplying natural botanicals, multi-minerals, and other raw materials.

What Industry Does INBP Operate In?

Integrated BioPharma, Inc. (INBP) operates within the Packaged Foods industry, specifically focusing on the dynamic and expanding nutraceuticals and dietary supplements segment of the broader Consumer Defensive sector. This industry is currently experiencing robust growth, driven by increasing consumer awareness of preventative health, an aging global population, and a rising preference for natural and wellness-focused products. Market trends indicate a sustained demand for vitamins, herbal remedies, and specialized nutritional supplements, with significant opportunities in both branded and private-label offerings. INBP's positioning is somewhat unique due to its dual operational segments. The Contract Manufacturing division places it within the B2B supply chain for nutraceuticals, competing with other specialized manufacturers who offer formulation and production services. This segment benefits from the outsourcing trends within the industry, as brands seek efficient and compliant manufacturing partners. Concurrently, its Other Nutraceutical Businesses segment, with proprietary brands like Peaceful Sleep and Wheatgrass, and its private-label online sales, positions INBP directly in the B2C retail landscape. Here, it competes with a vast array of established supplement brands, pharmaceutical companies with wellness divisions, and numerous smaller, agile direct-to-consumer brands. The competitive landscape is fragmented, characterized by continuous product innovation and evolving consumer preferences, necessitating strong brand loyalty and efficient distribution networks to gain market share.

Who Are INBP's Key Customers?

  • Distributors of nutritional supplements and health products.
  • Multi-level marketing firms in the wellness industry.
  • Professional healthcare practitioners seeking custom formulations.
  • General retailers, supermarkets, pharmacies, and specialty vitamin stores.
  • Direct-to-consumer online customers purchasing private-label and proprietary products.
Model self-rating on this text: 69% (not a measure of the evidence) Updated: Jun 15, 2026

Research confidence

Low 34/100

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • Scoring coverage unknown
  • Price is current
  • Latest filing 126 days ago
  • No analyst coverage

MoonshotScore History

Recorded daily since 2026-08-23 · 20 snapshots

2026-08-23 40
2026-08-27 40
2026-08-31 40
2026-09-04 40
2026-09-08 40
2026-09-11 40

What changed?

The score has stayed at 40.

Over the same 19 days the stock moved -8.3%.

Integrated BioPharma, Inc. Financial Trajectory

Integrated BioPharma, Inc. (INBP) reported $10.1M in revenue for Q3 FY2026, a decline of 10.4% compared to the prior quarter. The company recorded a net loss of $837K, with diluted EPS of $-0.03. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Consumer Defensive stock should monitor closely. Across the four most recent quarters, INBP averaged $-0.01 in diluted EPS.

Company Profile

Integrated BioPharma, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Hillside, US. The company is led by CEO Riva Sheppard. INBP has traded publicly since 1996.

How Integrated BioPharma, Inc. Is Valued

Integrated BioPharma, Inc. carries a market capitalization of $5.12M, placing it in the micro-cap category.

ROE -8%

Key Financial Metrics

Return on equity for Integrated BioPharma, Inc. stands at -8.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -6.2%, showing how much profit it generates from its asset base. Its free cash flow yield is 50.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.25 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -29.6%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9

Financial Health

Integrated BioPharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.93 places it in the distress zone, a signal of elevated financial risk.

Net selling

Insider Activity

Over the past six months, Integrated BioPharma, Inc. insiders filed 17 SEC Form 4 transactions — 8 sales and 9 purchases. On net that is roughly 12.3M shares disposed (about $48K), a signal worth weighing alongside the fundamentals.

INBP Financials

Fundamental Snapshot

Revenue Growth (FY)
+8.0%
Free Cash Flow Growth (FY)
+380.5%
Return on Equity (TTM)
-8.3%
Current Ratio
3.3
EV/EBITDA (TTM)
55.5

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Dual business model provides diversified revenue streams from contract manufacturing and branded product sales.
  • Established proprietary brands such as Peaceful Sleep and Wheatgrass with market presence.
  • Integrated services including manufacturing, warehousing, and order fulfillment.
  • Long operating history since 1980, indicating experience and stability in the industry.

Bear Case

  • Negative profit margin of -3.4% indicates current unprofitability.
  • Low gross margin of 4.6% suggests limited pricing power or high production costs.
  • Small market capitalization of $5.12M, potentially limiting access to capital.
  • OTC Other listing implies less stringent disclosure requirements and potentially lower liquidity.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q3 FY2026 $10M -$837,000 -$0.03
Q2 FY2026 $11M -$762,000 -$0.02
Q1 FY2026 $13M $123,000 $0.0039
Q4 FY2025 $14M -$178,000 -$0.01

Q3 FY2026 · filed 8 May 2026 · SEC EDGAR →

Based on FMP financials and quantitative analysis

INBP Latest News

INBP Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for INBP.

Price Targets

Wall Street price target analysis for INBP.

INBP MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for INBP; grades run from A+ (80-100) to F (below 30).

Leadership: Riva Kay Sheppard

Chief Executive Officer

Riva Kay Sheppard serves as the Chief Executive Officer of Integrated BioPharma, Inc., overseeing all strategic and operational aspects of the company. While specific details regarding her educational background and prior career history before joining INBP are not publicly available, her current role involves managing a workforce of 147 employees across the company's diverse operations in contract manufacturing and nutraceutical product distribution. Her leadership is central to guiding INBP's efforts in the creation, promotion, and sale of vitamins, nutritional supplements, and herbal items across its key markets in the United States, Luxembourg, and Canada.

Track Record: Under Riva Kay Sheppard's leadership, Integrated BioPharma, Inc. has continued to operate its dual business model, maintaining its presence in both contract manufacturing and the distribution of proprietary and private-label wellness products. Key strategic decisions likely involve navigating the competitive nutraceutical market, optimizing supply chain operations, and managing the company's financial performance, including its current profitability challenges. Her tenure has seen the company sustain its operational footprint and product offerings, including brands like Peaceful Sleep and Wheatgrass, in a dynamic consumer defensive sector.

INBP OTC Market Information

Integrated BioPharma, Inc. (INBP) is classified as an "OTC Other" stock, which is the lowest tier on the OTC Markets Group's quotation system. Unlike companies listed on major exchanges such as the NYSE or NASDAQ, which have stringent listing requirements regarding financial standards, corporate governance, and minimum share prices, OTC Other companies face significantly less rigorous criteria. This tier is typically reserved for companies that do not meet the disclosure standards for OTCQX or OTCQB, or those that have chosen not to provide current information. It signifies a market with potentially limited public information and higher risk compared to more transparently traded securities.

  • OTC Tier: OTC Other
Liquidity: As an OTC Other listed entity, INBP inherently carries risks associated with potentially lower liquidity. This means that the volume of shares traded daily might be low, leading to wider bid-ask spreads and difficulty in executing large orders without significantly impacting the stock price. Investors might find it challenging to buy or sell shares quickly at desired prices. The limited trading activity can also contribute to price volatility and make it harder to ascertain a fair market valuation for the company's stock.
OTC Risk Factors:
  • Less stringent disclosure requirements compared to major exchanges, leading to limited available financial and operational information.
  • Potentially lower trading volume and wider bid-ask spreads, resulting in reduced liquidity and difficulty in executing trades.
  • Increased susceptibility to market manipulation due to lower trading transparency and oversight.
  • Limited analyst coverage and institutional investor interest, which can hinder price discovery and market efficiency.
  • Higher volatility and potential for significant price swings due to the smaller market capitalization and limited public float.
Due Diligence Checklist:
  • Verify the company's most recent financial statements and annual reports, if available, directly from the company or regulatory filings.
  • Research any news releases, corporate actions, or material events that may impact the company's operations or stock price.
  • Assess the company's management team and their track record, looking for experience and stability.
  • Investigate the competitive landscape and market position of INBP's products and services within the nutraceutical industry.
  • Evaluate the company's capital structure, debt levels, and cash flow generation capabilities.
  • Understand the regulatory environment for dietary supplements in its operating regions (US, Luxembourg, Canada).
  • Scrutinize the trading volume and bid-ask spread to gauge liquidity before considering an investment.
Legitimacy Signals:
  • Long operating history since 1980, indicating established operations rather than a recent shell company.
  • Physical headquarters in Hillside, New Jersey, suggesting a tangible business presence.
  • Identified CEO, Riva Kay Sheppard, and a stated employee count of 147, indicating an active organizational structure.
  • Clear business description with two distinct operational segments (Contract Manufacturing and Other Nutraceutical Businesses).
  • Proprietary brands (Peaceful Sleep, Wheatgrass) and defined product offerings, demonstrating tangible assets and market activities.

Integrated BioPharma, Inc. Consumer Defensive Stock: Key Questions Answered

Is INBP a good stock?

Stock Expert AI does not rate INBP buy, sell or hold. Integrated BioPharma, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.

What are the main risks for INBP?

Integrated BioPharma, Inc. faces several key risks that investors may want to evaluate. Financially, the company reported a negative profit margin of -3.4% and a low gross margin of 4.6%, indicating profitability challenges that could impact its long-term financial health and ability to generate sustainable returns.

What are the key factors to evaluate for INBP?

Evaluate INBP on fundamentals, analyst consensus, and risk factors. With a market capitalization of $5.12M, INBP operates as a micro-cap entity. Not financial advice.

How frequently does INBP data refresh on this page?

INBP's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.

What has driven INBP's recent stock price performance?

Integrated BioPharma, Inc. (INBP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Dual business model provides diversified revenue streams from contract manufacturing and branded product sales. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider INBP overvalued or undervalued right now?

Integrated BioPharma, Inc. (INBP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of INBP?

Yes, most major brokerages offer fractional shares of Integrated BioPharma, Inc. (INBP) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track INBP's earnings and financial reports?

Integrated BioPharma, Inc. (INBP) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for INBP earnings announcements.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

MoonshotScore is not published for this security.

Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • All information is derived solely from the provided source data. No external research or speculation was used.
  • Specific details regarding CEO's background, track record, and tenure are limited in the provided source.
  • The 'Unknown' disclosure status for OTC analysis is directly from the source data and impacts the depth of financial insight.
  • The provided FMP peer ticker 'INDFY' appears to be in a different sub-industry (agricultural inputs) than INBP's primary nutraceutical focus, as noted in the competitors section.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

More Stocks We Cover